key: cord-0844290-s9g6xdox
authors: Paolucci, Stefania; Cassaniti, Irene; Novazzi, Federica; Fiorina, Loretta; Piralla, Antonio; Comolli, Giuditta; Bruno, Raffaele; Maserati, Renato; Gulminetti, Roberto; Novati, Stefano; Mojoli, Francesco; Baldanti, Fausto
title: EBV DNA increase in COVID-19 patients with impaired Lymphocyte subpopulation count
date: 2020-12-21
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2020.12.051
sha: 3bfe207025503336e48efcf787ac223fdf634e9c
doc_id: 844290
cord_uid: s9g6xdox

Objectives The immunologic profile and opportunistic viral DNA increase were monitored in Italian patients with COVID-19 in order to identity markers of disease severity. Methods A total of 104 patients infected with SARS-CoV-2 were evaluated in the study. Of them, 42/104 (40.4%) were hospitalized in an intensive care unit (ICU) and 62/104(59.6%) in a sub-intensive care unit (SICU). Human cytomegalovirus (HCMV) and Epstein-Barr virus (EBV), Parvovirus B19 and Human Herpesvirus 6 virus reactivations were determined by real-time PCR, and lymphocyte subpopulation counts were determined by flow cytometry. Results Among opportunistic viruses, only EBV was consistently detected. EBV DNA was observed in 40/42 (95.2%) of the ICU patients and in 51/61 (83.6%) of the SICU patients. Comparing the two groups of patients, the EBV DNA median level among ICU patients was significantly higher than that observed in SICU patients.In parallel, a significant reduction of CD8 T cell and NK count in ICU patients as compared with SICU patients was observed (p < 0.05). In contrast, B cell count was significantly increased in ICU patients (p = 0.0172). Conclusions A correlation between reduced CD8+ T cells and NK counts, EBV DNA levelsand COVID-19 severity was observed. Other opportunistic viral infections were not observed. The relationship between EBV load and COVID-19 severity should be further evaluated in longitudinal studies.

Coronavirus disease 2019 , caused by severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2), was first reported in China in December, 2019. As of February 21, 2020, more than 7,151,000 cases of COVID-19 have been reported worldwide and there are more than 407,145 deaths. The spread has already taken on pandemic proportions, affecting over 100 countries, including Italy that counts more than 235,270 cases (1, 2) . In February 2020, a large COVID-19 outbreak in Lombardy Italy was observed. SARS-CoV-2 influence on immunological response, and its relationship with the reactivation of opportunistic viral infection in the clinical course of COVID-19 is still under investigation. Among various pathogens, opportunistic viral infections such as human cytomegalovirus (HCMV) and Epstein-Barr virus (EBV) are particularly relevant in immunocompromised patients (3, 4) and their reactivation has also been reported in patients in intensive care units (ICU) with no previous immune suppression (5) (6) (7) (8) (9) (10) .

On the other hand, the impact of opportunistic viral reactivation in critically ill patients remains to be elucidated.

Finally, the impact of COVID-19 infection on the immune system is not yet well known. In this study, a possible relationship with alterations of the NK and T-cell subpopulations leading to opportunistic virus reactivation were analyzed in patients with COVID-19 having different degrees of severity.

Written informed consent was collected. A total of 104 patients infected with SARS-CoV-2 referred to the Fondazione IRCCS Policlinico San Matteo, Pavia between February 2020 and March 2020 were evaluated. Of them, 42/104 (40.4%) were hospitalized in an ICU and 62/104 (59.6%) were hospitalized in a sub-intensive care unit (SICU). The degree of severity of COVID-19 (severe vs J o u r n a l P r e -p r o o f mild) was defined using the American Thoracic Society guidelines for community-acquired pneumonia (11) . Patient characteristics and comorbidity were described in Table 1 .

Antiviral capsid antigen (anti-VCA), anti-EBNA, anti-HCMV and anti-parvovirus B19 specific IgG were quantified from serum samples using a chemiluminescent assay according to manufacturers' instructions (Liaison, Diasorin, Saluggia, Italy). Positive results were defined as IgG> 20U/ml for VCA and EBNA IgG, IgG>14 U/ml for CMV IgG and Index>1.1 for Parvovirus B19 IgG. targeting RNA-dependent RNA polymerase and E genes were used to detect the presence of SARS-CoV-2 according to the WHO guidelines (12) and Corman et al. protocols (13) . The CMV DNA and EBV DNA load were determined by home-made real-time PCR in CMV and EBV seropositive subjectsusing primers and probesand Applied Biosystems Instrument (ThermoFisher,Waltham, Massachusetts, United States) as reported (14, 15) . At the same time, Parvovirus B19 and Human Herpesvirus 6were analyzed in a fraction of patients (16, 17) .

Blood samples were stained with CYTO-STAT tetraCHROME CD45-FITC/CD4-RD1/CD8-ECD/CD3-PC5 and CYTO-STAT tetraCHROME CD45-FITC/CD56-RD1/CD19-ECD/CD3-PC5, all from Beckman Coulter, Milan, Italy).The percentage of CD4+ and CD8+ T J o u r n a l P r e -p r o o f lymphocytes and CD56+ NK and CD19+ B cells was determined by Navios Flow Cytometer System (Beckman Coulter). Using FlowCountFluorospheres, CD4+, CD8+ T cell subsets and CD56+ NK and CD19+ B cells were expressed as absolute counts (cells/µl). Gating strategy was set up on CD45 + and side scatter (SSC).

Descriptive data were reported or considered as absolute and relative frequencies, median and interquartile range (IQR) based on the type of variable distribution. For qualitative variables, Fisher's test was used, while the Mann-Whitney test was used for quantitative variables in order to perform comparison between groups. Spearman's test was used for the correlation analysis. All tests were two-tailed. A p-value <0.05 was considered statistically significant. Analyses were performed using the GraphPad Prism 5 (GraphPad Software, CA, USA).

Male COVID-19 patients were more frequent in both units (p=0.039). The most common symptoms detected in patients on admission or during hospitalization in ICU and SICU, respectively, were fever (80.9% and 100%; p=0.02), interstitial lung disease (100% and 55.6%; p<0.001), dyspnea (100% and 37%; p<0.001), and diarrhea ( 

The strict relation between immunosuppression and reactivation of latent viruses and an increased prevalence of opportunistic viral infections is well known, especially in transplanted patients and in ICU patients (4, (5) (6) (7) (8) (9) (10) .

The impact of COVID-19 infection on the immune system is still largely unknown. We observed a significant loss of NK and CD8 + T cells in COVID-19 patients, which paralleled the severity of the infection. Normally, in healthy subjects lymphocytes CD3 + counts range from690 to 2540 cells/µl, lymphocytes CD4 + and CD8 + counts range from 410 to 1590 and from 190 to 1140 cells/µl, respectively; moreover, in healthy subjects, we reported that CD19 + B cell counts and CD56+ NK cell counts range from 163 to 288 cells/µl and from 151-296 cells/µl. Surprisingly, this NK and CD8 + T cell reduction was associated with presence of EBV DNA only.Despite the large majority of patients were seropositive for both CMV and B19, no evidence of circulating CMV and B19 DNA was observed. In this study, we analyzed the correlation between COVID-19 infection and immunological and virological factors, classifying patients according to the severity of the COVID-19 disease. Overall, a higher proportion of interstitial lung disease and dyspnea was observed among ICU patients as compared to SICU patients (p<0.001). Interestingly, positive EBV DNA was observed in approximately 87% of patients. The rate of positive EBV DNA observed was higher in COVID-19 patients with severe infection (ICU patients) as compared to patients with mild symptoms (SICU patients). Moreover, the median EBV DNA levels in patients with severe COVID-19 was significantly higher than in patients with mild COVID-19 disease, supporting the evidence of a higher immune impairment in the previous patients. However, no linear correlation between EBV DNA load and lymphocytes' counts was observed.In line with these results, a reduced total lymphocyte count in patients referred to ICU was observed, reporting a significant reduction in terms of both CD8 + and NK cells as compared to SICU patients, while no significant reduction of CD4 + T cell counts was observed. Recent studies underlined a marked lymphopenia in a large fraction of COVID-19 patients (18, 19) with a reduction of total T lymphocytes, CD4 + T cells and CD8 + T cells and a more profound reduction in severe cases (20) . Interestingly, among all opportunistic viruses, reactivation in COVID-19 patients seems to be restricted to EBV, an event somewhat corroborating a role in the severity of the disease. In fact, despite the low rate of CD8 + T cells and NK cells in patients with severe symptoms, CMV reactivation, for example, was never observed. Usually, detectable CMV DNA in whole blood is more frequent than EBV DNA in immunocompromised patients with reduced lymphocyte counts.

In conclusion, our data support the possible correlation between lymphopenia and EBV load with COVID-19 disease severity. In order to corroborate our hypothesis, monitoring of the immunological profile and opportunistic virus reactivation over time is warranted in order to better understand the role in the pathogenesis of the disease or its relationship with the severity of symptoms. 

First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA

COVID-19 and Italy: what next?

Infection in Organ Transplantation

Overview: cytomegalovirus and the herpesviruses in transplantation

Cytomegalovirus: A Troll in the ICU? Overview of the Literature and Perspectives for the Future

CMV in critically ill patients: pathogen or bystander

Cytomegalovirus reactivation in a general, non-immunosuppressed intensive care unit population: incidence, risk factors, associations with organ dysfunction, and inflammatory biomarkers

Epidemiology of Multiple Herpes Viremia in Previously Immunocompetent Patients with Septic Shock.Molecular Diagnosis and Risk Stratification of Sepsis Consortium

Martin-Loeches I. Influenza Infections and Emergent Viral Infections in Intensive Care Unit

Cytomegalovirus and Epstein-Barr virus reactivation in the intensive care unit

Diagnosis and treatment of adults with community-acquired pneumonia: an official clinical practice guideline of the

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Kinetics of Epstein-Barr virus DNA load in different blood compartments of pediatric recipients of T-cell-depleted HLA-haploidentical stem cell transplantation

Kinetics of human cytomegalovirus (HCMV) DNAemia in transplanted patients expressed in international units as determined with the Abbott RealTime CMV assay and an in-house assay

Genetic variants of human parvovirus B19 in South Africa: cocirculation of three genotypes and identification of a novel subtype of genotype 1

Real-time quantitative PCR assays for detection and monitoring of pathogenic human viruses in immunosuppressed pediatric patients

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study

Clinical and immunologic features in severe and moderate Coronavirus Disease

Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia

We thank Daniela Sartori for careful preparation of the manuscript.